{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-041807","form_type":"8-K/A","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2026-09-08T21:29:33+00:00","discovered_at":"2026-09-08T21:30:00.364957+00:00","generated_at":"2026-09-08T21:30:08.297829+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vivos exchanges $2.86M Streeterville debt for 11.45M shares, 52% dilution","bullets":["Exchanged $2,861,270 of Streeterville Note principal for 11,445,080 common shares (avg $0.25/share) on Sept 2, 2026.","Shares represent ~52% of pre-exchange outstanding (22,164,313) and ~34% of post-exchange (33,609,393).","Following exchanges, Streeterville Note balance reduced to $3.7 million; no cash proceeds received.","Exchanges done via 12 agreements; shares unregistered, issued under Section 3(a)(9).","Amendment corrects original 8-K report date to Sept 2, 2026; transactions consummated that date."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-041807","json":"https://secwatch.observer/filing/0001493152-26-041807.json","markdown":"https://secwatch.observer/filing/0001493152-26-041807.md","text":"https://secwatch.observer/filing/0001493152-26-041807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226041807/0001493152-26-041807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226041807/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T21:30:08.297829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}